首页/数据集/Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines

Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines

NIAID Data Ecosystem2026-03-12 收录

乳腺癌内分泌治疗耐药

ESR1基因突变分析

数据链接：

https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100076 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

应用场景：

创建时间：

2021-07-25

乳腺癌内分泌治疗耐药

RNA调控机制

Full title: Expression data from antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells The expression of miR-221/222 were found to be upregu

NIAID Data Ecosystem60

Quantitative proteomics on wt-MCF7 versus their LTED derivatives using dimethyl labelling

乳腺癌内分泌治疗耐药

定量蛋白质组学

Wild type (wt) MCF7 cells, modelling breast cancer at primary diagnosis, were cultured in phenol red-free RPMI supplemented with 10% FBS and 1nM estradiol (E2). Long-term oestrogen deprived (LTED) cel

NIAID Data Ecosystem50

The NF?B pathway promotes endocrine therapy tolerance through activation of integrated stress response in ER positive breast cancer

乳腺癌内分泌治疗耐药

整合应激反应机制

While estrogen receptor positive breast tumors generally respond well to endocrine therapy (ET), up to 40% of patients will experience relapse, either while on endocrine therapy or after ET is complet

NIAID Data Ecosystem40

GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer [ChIP-seq]. GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer [ChIP-seq]

乳腺癌内分泌治疗耐药

FOXA1/GRHL2转录调控

The estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen recepto

NIAID Data Ecosystem60

High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer

乳腺癌内分泌治疗耐药

CDK6生物标志物预测

Purpose: Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole was appr

NIAID Data Ecosystem50

Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines

资源简介：

相关数据集